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Abstract 
Tridecaptin A1 (TriA1) is a non-ribosomal lipopeptide with selective antimicrobial 
activity against Gram-negative bacteria. Herein we show that TriA1 exerts its 
bactericidal effect by binding to the bacterial cell wall precursor lipid II on the 
inner-membrane, disrupting the proton motive force. Biochemical and biophysical 
assays show that binding to the Gram-negative variant of lipid II is required for 
membrane disruption, and that only the proton gradient is dispersed. The NMR 
solution structure of TriA1 in dodecylphosphocholine micelles with lipid II has 
been determined and molecular modeling was used to provide a structural model 
of the TriA1-lipid II complex. These results suggest that TriA1 kills Gram-negative 
bacteria by a novel mechanism of action using a new lipid II binding motif. 
Significance 
The increasing development of antimicrobial resistance is a major global concern 
and there is an urgent need for the development of new antibiotics. In this article 
we show that the antimicrobial lipopeptide tridecaptin A1 selectively binds to the 
Gram-negative analogue of peptidoglycan precursor lipid II, disrupting the proton 
motive force and killing Gram-negative bacteria. To the best of our knowledge 
this is the first example of the selective targeting of Gram-negative lipid II and a 
completely new binding mode to this peptidoglycan precursor. No persistent 
resistance develops against tridecaptin A1 in E. coli cells exposed to sub-
inhibitory concentrations of this peptide during a one-month period. We believe 
this study showcases the excellent antibiotic properties of the tridecaptins in an 
age where new antibiotics that target Gram-negative bacteria are desperately 
needed. 
 
\body 
Introduction 
Recently, a lot of media coverage has been focused on the problem of 
antimicrobial resistance. A report commissioned by the UK government predicts 
that by 2050, antimicrobial resistance will have caused 300 million premature 
deaths and cost the global economy over $100 trillion.(1) Even more worrying is 
the lack of new classes of antibiotics active against Gram-negative bacteria. In 
the last 50 years, only a few structurally and mechanistically distinct classes of 
antibiotics have been clinically approved to treat systemic infections (including 
fidaxomicin, bedaquiline, linezolid and daptomycin), yet none of these are active 
against Gram-negative bacteria.(2),(3) Two new classes of Gram-negative 
targeting antibiotics in the clinical pipeline are POL7080 and brilacidin.(4),(5) Both 
of these compounds are modeled on antimicrobial peptides, which are becoming 
increasing important in the fight against antibiotic resistance.(6) Bacteria produce 
a wealth of antimicrobial peptides, both ribosomally, including the 
lantibiotics,(7),(8) and non-ribosomally, including lipopeptides.(9) In particular, 
lipopeptides are a rich source of antimicrobial compounds and several examples 
with activity against Gram-positive(10),(11) and/or Gram-negative bacteria(12) 
have been recently characterized. 
Tridecaptin A1 (TriA1) is a member of the tridecaptin family, a group of 
non-ribosomal lipopeptides produced by Bacillus and Paenibacillus species (Fig. 
1).(13),(14),(15) This acylated tridecapeptide displays strong and selective 
antimicrobial activity against Gram-negative bacteria, including multidrug 
resistant strains of Klebsiella pneumoniae, Acinetobacter baumannii and 
Escherichia coli.(16) TriA1 analogues have low cytotoxicity and have been shown 
to treat Klebsiella pneumoniae infections in mice.(16),(17) Therefore, we believe 
that tridecaptin A1 could be an excellent antibiotic candidate. However, prior to 
our investigations little was known about how TriA1 exerts its selective 
bactericidal effect against Gram-negative bacteria. A previous structure activity 
relationship study by our group suggested that TriA1, akin to many other 
lipopeptides, is a membrane-targeting agent. We found that removal of the N-
terminal lipid tail abolishes antimicrobial activity, however the chiral lipid tail could 
be replaced with an octanoyl chain to give Oct-TriA1 (Fig. 1), which retains full 
activity.(16) We therefore sought to identify the precise mode and mechanism of 
action by which TriA1 kills Gram-negative bacteria. 
 
Results 
Tridecaptin A1 targets the cell membrane 
Our initial efforts focused on identifying the mode of action of TriA1. 
Measuring the time taken for an antibiotic to exert its antimicrobial effect can 
provide valuable information on the cellular process targeted by that compound. 
Bacteriostatic agents halt cell division but do not reduce the number of viable 
cells and antibiotics that target protein synthesis and nucleic acid synthesis 
typically fall within this category. Bactericidal agents reduce the population of 
viable bacterial cells and the time taken for a bactericidal agent to kill bacteria 
provides further information on its target. Therefore, we monitored the growth 
kinetics of Escherichia coli cells exposed to TriA1 and a number of other 
antibiotics (Fig. 2). Lipopeptides like polymyxin B are generally bactericidal within 
minutes of exposure, due to the formation of large, non-specific pores in the 
bacterial membrane, while many other antibiotics (like ampicillin) exert their 
killing effect over several hours. Bacteriostatic agents (like chloramphenicol) halt 
cell growth, but do not kill cells. Optical density measurements showed that cells 
exposed to TriA1 grew at a reduced rate for 20 minutes, at which point a steady 
decrease in cell count was observed (Fig. 2A). Polymyxin B reduced the cell 
count immediately, while ampicillin displayed an expected three-hour lag and 
chloramphenicol did not reduce optical density. Complementary results were 
obtained from a time-kill assay (Fig. 2B), which revealed that cells exposed to 
TriA1 showed slightly reduced cell viability after 15 minutes of exposure, a 
significant reduction after 30 minutes and complete killing after 60 minutes. 
Polymyxin B acted faster, significantly reducing the viable cell population after 5 
minutes and killing all cells by 30 minutes. These results suggested that TriA1 is a 
membrane targeting peptide, but does not act by a generic membrane lysis 
mechanism like polymyxin B. This is further supported by the selectivity of TriA1 
against Gram-negative bacteria, as a peptide that operates through a generic 
lysis mechanism would also target Gram-positive organisms. 
 
TriA1 binds to lipopolysaccharide on the outer-membrane 
Gram-negative organisms are protected from their environment by an 
outer-membrane, which reduces diffusion of many antibiotics into the cell or 
periplasmic space. In order for TriA1 to attack the bacterial membrane of Gram-
negative bacteria, it must first cross this barrier. Polymyxin B traverses the outer-
membrane by binding to the lipid A portion of lipopolysaccharide (LPS), followed 
by insertion into the membrane.(18) We postulated that tridecaptin A1 may also 
cross the outer-membrane through an interaction with LPS, given that it possess 
several cationic 2,4-diaminobutyric acid residues (Dab) like polymyxin B. 
Isothermal titration calorimetry (ITC) was therefore used to determine if TriA1 
binds to LPS. Our studies revealed that TriA1, Oct-TriA1, the enantiomeric form of 
TriA1 (Ent-TriA1) and unacylated TriA1 (H-TriA1) bind to LPS with similar affinities 
(SI Appendix, Fig. S1). We have previously shown that H-TriA1 has weak 
antimicrobial activity, but at sub-MIC concentrations it can enhance the activity of 
hydrophobic antibiotics like rifampicin and vancomycin over 100-fold.(17) 
Therefore, it is likely that LPS binding is the mechanistic basis for this disruption 
of the outer-membrane. We have also found that the enantiomer of TriA1 (Ent-
TriA1) is four-fold less active than the natural peptide, suggesting that TriA1 
interacts with a chiral target.(19) Ent-TriA1 contains the same amino acids and 
lipid tail as TriA1, and therefore retains the same amphiphilic properties. It is likely 
that the observed activity at higher concentrations is due to membrane lysis by a 
non-specific detergent-like effect, akin to the mode of action of the polymyxins. 
This observation that both TriA1 and its enantiomer bind to LPS with similar 
affinities suggested that another chiral receptor is involved in the mode of action.  
 
TriA1 disrupts the proton motive force 
 With a rationale for how TriA1 crosses the outer-membrane, we next 
sought to uncover the mechanism by which it acts on the inner-membrane. To 
this end, a series of experiments were performed using fluorescent dyes (Fig. 3). 
DiBAC4 is a common dye used to monitor membrane depolarization.(20) It enters 
depolarized cells and binds to proteins or membrane components, exhibiting 
enhanced fluorescence. Addition of TriA1 to DiBAC4 treated E. coli cells resulted 
in no membrane depolarization, whilst application of polymyxin B lead to a rapid 
increase in fluorescence (Fig. 3A). To further assess the effect of TriA1 on the 
inner-membrane, its ability to form large pores was assessed using the dye 
SYTOX Green (Fig. 3B). Upon lysis of the inner-membrane, this dye binds to 
nucleic acids in the cytoplasm, causing an increase in fluorescence.(21) 
Immediate pore formation was not observed when E. coli cells pretreated with 
SYTOX Green were exposed to TriA1, whereas addition of the surfactant Triton 
X-100 caused an instant fluorescence increase. Instead, TriA1 caused a very 
gradual increase in fluorescence at a rate consistent with the death of cells 
based on the time-kill assays, suggesting that this increase is due to cells that 
are already dead and not an immediate effect of TriA1. To further probe the 
action of TriA1 on the inner membrane, an ortho-nitrophenyl-β-galactosidase 
(ONPG) assay was performed on E. coli ML-35 cells, which lack the lac 
permease. The chromophore ortho-nitrophenol is released by the action of 
cytoplasmic galactosidase on ortho-nitrophenol galactoside only if large pores 
are formed on the inner-membrane. ONPG assays (SI Appendix, Fig. S2) did not 
show immediate membrane lysis upon TriA1 addition to E. coli cells. 
The rapid killing of E. coli by TriA1 stood in stark contrast to the lack of 
membrane lysis or depolarization observed. The essential nature of the 
hydrophobic tail for antimicrobial activity and the overall amphiphilic structure of 
TriA1 support an interaction with the bacterial membrane, therefore we examined 
the function of the inner-membrane in detail. Bacteria use both protons and 
potassium ions to generate adenosine triphosphate (ATP) via the proton motive 
force, a process that is essential for cell growth.(22),(23) Other antibiotics are 
known to affect this vital cellular process. For example, nigericin and valinomycin 
shuttle a combination of K+ and H+ across the bacterial membrane,(23) while the 
bacteriocin subtilosin forms proton-specific pores in the Gram-positive bacterium 
Gardnerella vaginalis.(24),(25) To determine if TriA1 affects the proton motive 
force, we adapted the pro-dye BCECF-AM for use in Gram-negative bacteria. In 
the presence of ethylenediaminetetraacetic acid (EDTA), this dye readily crosses 
the bacterial membrane where it is hydrolyzed by non-specific esterases to give 
a pH sensitive dye, whose fluorescence decreases as cytoplasmic pH 
decreases.(25) Addition of glucose to BCECF-AM treated E. coli cells resulted in 
a fluorescence increase, indicating they were actively respiring and that BCECF 
was correctly showing the increase in cytoplasmic pH (Fig. 3C). To assess the 
effect on the proton gradient, the potassium gradient was first dispersed by 
addition of valinomycin, which exchanges K+ with H+, causing a small increase in 
fluorescence. Subsequent addition of TriA1 resulted in a significant fluorescence 
decrease, signifying pore formation and disruption of the proton gradient. 
Addition of the proton shuttle peptide nigericin also had a similar but more rapid 
effect, strongly suggesting that TriA1 disrupts the proton motive force. 
 
TriA1 selectively binds to Gram-negative lipid II 
Having identified a probable mode of action for tridecaptin A1, we next 
sought to identify the chiral receptor involved in its mechanism of action. Given 
the lower antimicrobial activity of the Ent-TriA1, and the fact that TriA1 acts on the 
bacterial membrane, we postulated that binding of TriA1 to a chiral receptor on 
the surface of the inner-membrane is important. Lipid II is the final monomeric 
intermediate in peptidoglycan biosynthesis and a target of several antimicrobial 
peptides, including nisin,(26),(27) plectasin(28) and teixobactin.(10) It is 
synthesized in the cytoplasm and anchored to the interior of the inner-membrane 
by an undecaprenyl chain. Lipid II is subsequently flipped to the exterior of the 
inner-membrane, where it is then elongated into peptidoglycan. The structure of 
lipid II differs between Gram-positive and Gram-negative bacteria, namely on 
residue three of the pentapeptide portion. In most Gram-negative bacteria, this 
amino acid is meso-diaminopimelic acid (DAP), whereas in most Gram-positive 
bacteria it is lysine (Fig. 4A). Using ITC, we evaluated the binding affinity of TriA1 
to Gram-negative (Fig. 4B) and Gram-positive lipid Il (SI Appendix, Fig. S3). TriA1 
binds to Gram-negative lipid II in a 1:1 stoichiometry and with a Kd of 4 μM, which 
is close to the MIC of TriA1 against E. coli (~3 μM). We were surprised to find that 
although TriA1 binds strongly to Gram-negative lipid II, it has a much weaker 
binding affinity to the Gram-positive variant. This observation would explain why 
TriA1 is approximately 50-fold less active against Gram-positive bacteria, 
therefore we sought to further investigate this phenomenon. Gratifyingly, Ent-
TriA1 does not bind to Gram-negative lipid II (SI Appendix, Fig. S4), confirming 
that this is an important chiral receptor for TriA1. When TriA1 was premixed with 
one equivalent of Gram-negative lipid II, its activity was completely abolished in a 
spot-on-lawn assay against E. coli (Fig. 4C). In contrast, premixing TriA1 with 
Gram-positive lipid II had very little effect on the antimicrobial activity of the 
peptide, further evidencing this selective interaction. The same experiment with 
Ent-TriA1 and Gram-negative lipid II had not effect on activity (SI Appendix, Fig. 
S4). To the best of our knowledge, this is the first reported instance of an 
antimicrobial compound binding selectively to lipid II from Gram-negative 
bacteria. 
 
In vitro assays link lipid II binding to membrane disruption 
To corroborate our theory that TriA1 binds to lipid II on the inner-
membrane and disrupts the proton motive force, we developed an in vitro assay 
using large unilamellar vesicles (LUV) and BCECF acid to measure intravesicle 
pH changes. BCECF was encapsulated in 50 nm LUVs, such that the internal pH 
is set to pH 8.0 (Fig. 5A). Transferring these vesicles into a pH 6 buffer did not 
lead to an observable change in fluorescence over 30 minutes of incubation, 
whilst an immediate decrease was observed on the addition of triton X-100, 
confirming the integrity of the vesicles. Oct-TriA1, which has identical 
antimicrobial activity to TriA1 and also binds to Gram-negative lipid II, was used in 
these studies. Addition of Oct-TriA1 to LUVs containing 1 mol% Gram-negative 
lipid II at concentrations mimicking the bacterial MIC resulted in a rapid decrease 
in fluorescence, signifying pore formation (Fig. 5B). A much weaker decrease in 
fluorescence occurred with LUVs containing 1 mol% Gram-positive lipid II, which 
was comparable to the effect observed against vesicles lacking any lipid II. 
These studies provide further evidence that TriA1 selectively recognizes Gram-
negative lipid II and link this recognition to the observed bactericidal activity. 
 
 
 
Synthesis of Gram-negative lipid II analogue for NMR studies 
 In an effort to understand the interaction between TriA1 and Gram-
negative lipid II on a molecular level, we sought to elucidate the NMR solution 
structure of TriA1 in dodecylphosphocholine (DPC) micelles containing Gram-
negative lipid II. Natural lipid II, which contains a fatty undecaprenyl chain, is not 
very amenable to NMR studies. It is prone to micelle formation in aqueous 
solvent and the multiple methyl and methylene signals from the C55 chain can 
drown out important signals in its binding partner needed for complete structural 
characterization. Breukink and coworkers have previously shown that a Gram-
positive lipid II analogue with an (E,E)-farnesyl (C15) chain retains full binding 
affinity to nisin,(29) and this analogue was used in the elucidation of the NMR 
solution structure of the nisin-lipid II complex.(27) Although they found that the 
isoprene units in the chain were not necessary for nisin binding, it was unclear if 
this region of lipid II was required for interactions with TriA1. Therefore we 
embarked on the synthesis of (Z,Z)-farnesyl Gram-negative lipid II (1) (Fig. 6). 
The total synthesis of Gram-positive lipid II was previously reported by Van 
Nieuwenhze and coworkers,(30),(31) whereas a semi-synthesis of Gram-negative 
lipid II has been reported by Walker and Kahne.(32) By modification of these 
literature procedures, we performed the first total synthesis of Gram-negative 
lipid II analogue (1) (Fig. 6, SI Appendix). The disaccharide core was constructed 
by a glycosylation between acetimidate 2 (SI Appendix, Scheme S1) and glycol 3 
(SI Appendix, Scheme S2-S3). After protecting group manipulation and 
phosphorylation of the anomeric position of alanyl disaccharide 4, the appropriate 
tetrapeptide (5, SI Appendix, Scheme S4-S5) was coupled to the alanine 
carboxylate to yield pentapeptidyl disaccharide 6. Deprotection of the benzyl 
phosphate, followed by coupling to CDI activated (Z,Z)-farnesyl phosphate and 
global deprotection gave the desired Gram-negative lipid II analogue 1. 
 
Characterization of TriA1-lipid II complex by NMR and molecular modeling 
With Gram-negative lipid II analogue 1 in hand, we then proceeded to 
elucidate the NMR solution structure of Oct-TriA1 in DPC micelles doped with 
Gram-negative lipid II. First, the chemical shifts (SI Appendix, Table S1) and 
Nuclear Overhauser Effect (NOE) correlations of Oct-TriA1 in DPC micelles were 
assigned and its solution structure calculated using CYANA (SI Appendix, Fig. 
S5).(33) Without lipid II, Oct-TriA1 adopts a looped structure with all hydrophobic 
residues on one face. Upon addition of one equivalent of lipid II analogue 1 (SI 
Appendix, Table S2) to Oct-TriA1 in DPC micelles, significant amide chemical 
shift changes occurred on D-Val1, D-Dab2, and D-Dab8 in TriA1 (SI Appendix, 
Fig. S6); and on D-γ-Glu2, Ala4 and Ala5 in lipid II (SI Appendix, Fig. S7). This is 
indicative of a conformational change in both molecules and confirms they 
interact (SI Appendix, Tables S3-S4). With lipid II present, Oct-TriA1 adopts a 
more open and amphiphilic structure with an apparent π-stacking interaction 
between D-Trp5 and Phe9 (Fig. 7A). Interestingly, D-Dab8, which we have 
previously shown is the critical residue for Oct-TriA1 activity,(19) is located at the 
base of a possible binding pocket. 
To obtain an experimentally derived model of the Oct-TriA1-Lipid II 
complex, the structure of lipid II analogue 1 in the presence of Oct-TriA1 was also 
calculated using CYANA and then docked into the NMR solution structure of Oct-
TriA1 (Fig. 6A) using AutoDock Vina (Fig. 7B).(34) The model suggests that the 
N-terminal lipid tail and D-Trp5 are in close proximity to the lipid II terpene chain. 
This would be expected as the terpene tail of lipid II anchors it to the exterior of 
the inner-membrane and would associate with the more hydrophobic residues of 
TriA1. The model also suggests there is a H-bonding interaction between the γ-
amino group of D-Dab8 and the ε-carboxylate on DAP3 in lipid II (Fig. 7C). D-
Dab8 is essential for the antimicrobial activity of the tridecaptins and DAP3 in 
lipid II is essential for TriA1 binding. Notably, the model does not show 
interactions between Oct-TriA1 and the pyrophosphate moiety of lipid II. No shift 
in the 31P-NMR of lipid II is observed on addition of Oct-TriA1, confirming that the 
pyrophosphate is not involved in Oct-TriA1 binding (SI Appendix, Fig. S8). To the 
best of our knowledge, this is the first reported instance of an antimicrobial 
peptide that does not make use of a pyrophosphate cage. 
 
TriA1 displays low levels of resistance development 
The results from the mode of action and mechanism of actions studies 
suggested that tridecaptin A1 exerts its bactericidal effect by binding to lipid II on 
the inner-membrane and disrupting the proton motive force. Lipid II is a late 
stage intermediate in peptidoglycan biosynthesis, and the proposed binding site 
for TriA1 would be difficult for bacteria to modify without affecting its subsequent 
processing by enzymes in the peptidoglycan biosynthesis pathway. One would 
therefore expect that resistance development against TriA1 would be limited. An 
in vitro evolution study was performed, in which E. coli cells were continuously 
exposed to sub-MIC concentrations of Oct-TriA1 or ciprofloxacin for one month. 
During this experiment, the activity of the nucleic acid synthesis inhibitor 
ciprofloxacin decreased eight-fold, whereas no persistent resistance developed 
against Oct-TriA1 (Fig. 8). 
 
Discussion 
 We have shown that tridecaptin A1 exerts its bactericidal effect on Gram-
negative bacteria by binding to lipid II on the surface of the inner-membrane and 
disrupting the proton motive force. Monitoring the time taken for TriA1 to kill E. 
coli cells by growth kinetic measurements and time-kill assays suggested that it 
targets the cell membrane (Fig. 2). However, it does not act as quickly as 
polymyxin B, which kills bacteria by forming large non-specific pores on the 
inner-membrane. A study of the effect that TriA1 has on the bacterial membrane 
using fluorescent dyes (Fig. 3) revealed that TriA1 does not depolarize the 
membrane or kill Gram-negative bacteria by the formation of large pores. Initially 
this result was quite surprising as several pieces of evidence suggested that it 
interacts with the cell membrane. Firstly, the lipid tail of TriA1 is essential to its 
antimicrobial activity. This is similar for many other lipopeptides, which must 
insert their lipid tail into the cell membrane for membrane disruption. Also, the 
time taken by TriA1 to kill Gram-negative bacteria is consistent with membrane 
acting antibiotics and its overall amphiphilic structure further suggested a 
membrane interaction. This lead us to consider that TriA1 targets the bacterial 
membrane by a mode of action that is not membrane lysis. The proton motive 
force is a vital process that occurs across the bacterial membrane because it is 
the primary method by which bacteria produce ATP. The observation that other 
peptide antibiotics like nigericin, valinomycin and subtilosin can disrupt the proton 
motive force lead us to develop an in vivo assay using BCECF-AM to assess the 
impact that TriA1 has on this important cellular function. This experiment showed 
that addition of TriA1 rapidly decreases the cytoplasmic pH of E. coli cells, which 
was visualized as a rapid decrease in fluorescence (Fig. 3C). This signifies the 
formation of pores, allowing the transport of protons from the more acidic 
extracellular buffer into the cytoplasm. Combining this result with the observation 
that TriA1 does not depolarize the bacterial membrane or form large pores led us 
to conclude that TriA1 forms proton specific pores. This will ultimately block the 
synthesis of ATP and kill bacteria. 
 Having identified a probable mode of action, we next became interested in 
the mechanism of action. ITC revealed that like polymyxin B, TriA1 binds to LPS 
on the outer-membrane of Gram-negative bacteria. Removal of the lipid tail from 
TriA1 does not affect LPS binding but the unacylated derivative of TriA1 has 
substantially lower activity than the natural peptide. Therefore, the lipid tail is 
important for either outer- or inner-membrane penetration. The observation that 
the enantiomer of TriA1, which is less active than TriA1, binds to LPS with a 
similar binding affinity shows that another chiral receptor is involved in the 
mechanism of action. As several other antimicrobial peptides bind to the 
peptidoglycan precursor lipid II, which is presented on the surface of the inner-
membrane, we investigated if this was also a target for TriA1. A combination of 
ITC (Fig. 4B, SI Appendix, Fig. S1), inhibition assays (Fig. 4C) and in vitro 
assays (Fig. 5) provided compelling evidence that TriA1 selectively binds to the 
Gram-negative variant of lipid II, which contains DAP rather than lysine on its 
pentapeptide chain. TriA1 has strong activity against Gram-negative bacteria and 
strongly binds to lipid II from these organisms. Its activity is sequestered through 
complex formation with this analogue and the presence of Gram-negative lipid II 
in model membranes substantially increases the pore forming ability of TriA1. 
With TriA1 having much lower activity against Gram-positive bacteria, one would 
expect it to not bind very strongly to lipid II from these organisms, not lose activity 
when mixed with Gram-positive lipid II and not show increased activity against 
model membranes doped with Gram-positive lipid II. This is exactly what our 
experiments show. 
 We synthesized an analogue of Gram-negative lipid II and used this to 
calculate the NMR solution structure of tridecaptin A1 in DPC micelles containing 
one equivalent of Gram-negative lipid II (Fig. 7A). Molecular docking studies 
were then used to produce a model of the TriA1-lipid II complex (Fig. 7B-7C), 
which is supported by several lines of experimental evidence. Firstly, the amide 
chemical shifts of lipid II that underwent the largest change upon addition of Oct-
TriA1 are on the pentapeptide portion. Secondly, no interaction is predicted with 
the pyrophosphate of lipid II and no change in the 31P-NMR upon addition of Oct-
TriA1 to lipid II analogue 1 was observed. Thirdly and most importantly, a key 
hydrogen bond is predicted between the γ-amino group of D-Dab8 and the ε-
carboxylate on DAP3 in lipid II. A previous SAR study showed that D-Dab8 is 
absolutely essential for activity, and its substitution to D-Ala decreases its activity 
against Gram-negative bacteria to the level observed against Gram-positive 
organisms. If residue three on the pentapeptide portion of lipid II is lysine rather 
than DAP, the binding affinity of TriA1 is significantly reduced. Therefore, this 
predicted interaction perfectly describes these experimental observations and led 
us to conclude that it is the presence of DAP on lipid II that gives rise to the 
remarkable selectivity of tridecaptin A1 against Gram-negative bacteria. The 
observation that resistance development against Oct-TriA1 is limited (Fig. 8) is 
also important, given the lack of new antibiotics that target Gram-negative 
bacteria, and we believe that the tridecaptins are an attractive class of future 
antibiotic candidates. 
 
Materials and Methods 
Whole cell studies: See supplementary information. 
BCECF containing LUV preparation: 1,2-Dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) (16 mg) and 1,2-dioleoyl-sn-glycero-3-phospho-
(1'-rac-glycerol) (DOPG) (4 mg) were dissolved in chloroform (2 mL). If 
necessary G+LII or G-LII was then added as a solution in 2:3:1 
CHCl3:MeOH:H2O to 1 mol%. The solution was thoroughly mixed, the solvent 
was removed under reduced pressure and the film dried in the dark under high 
vacuum overnight. The desiccated lipids were rehydrated with potassium 
phosphate buffer (50 mM, pH 8, 2 mL) and BCECF acid (2 mM, 10 µL). In dim 
light the solution was shaken thoroughly, vortexed and transferred to a 5 mL 
cryovial. The vial was frozen in liquid nitrogen, and thawed at 37 oC. The lipids 
were shaken thoroughly until finely suspended and re-frozen. This process was 
repeated five times in total. The now finely dispersed vesicles were extruded 21 
times (back and forth 10.5 times) through a lipid extruder (Avanti Polar Lipids, 
AL) containing a 100 nm pore. Non-encapsulated dye was removed by passing 
the pale yellow solution through a Sephadex G-50 size exclusion column (50 mM 
potassium phosphate buffer as eluent, pH 8). The vesicles were then stored in 
the dark on ice at 4 oC for further use. Phosphate concentration was determined 
using the Stewart method.(35)  
In vitro assay using BCECF LUVs: Excitation and emission wavelengths were 
set to 500 nm and 522 nm respectively. Freshly prepared lipid vesicles (10 µL) 
were added to potassium phosphate buffer (50 mM, pH 6, 2 mL). The 
fluorescence was monitored, with stirring, for approximately 100 seconds to 
establish a baseline.  Oct-TriA1 was added, and fluorescence was monitored until 
stable. Triton X-100 (1%, 50 µL) was added to quench fluorescence.  
Experiments shown are representative of results from three technical replicates. 
NMR spectroscopy: Oct-TriA1 and lipid II were dissolved separately in 600 μl of 
a 180 mM dodecylphosphocholine-d38 (DPC) solution (10% D2O/90% H2O in 10 
mM sodium phosphate buffer at pH 6) to a final concentration of 4 mM. All 
spectra were referenced to the methylene protons in DPC at 1.52 ppm. One-
dimensional (1D) 1H-NMR and two-dimensional homonuclear (2D) 1H1-H total 
correlation spectroscopy (TOCSY) and Nuclear Overhauser Effect spectroscopy 
(NOESY) experiments were acquired at 27 °C on a four channel 600 MHz Varian 
VNMRS spectrometer with a HCN z-axis pulsed-field gradient probe. The 
acquisition software used was VNMRJ 4.2A. TOCSY and NOESY experiments 
used a 8,000 Hz spectral window in both the directly and indirectly detected 
dimensions. 512 experiments were used to define the indirectly detected 
dimension, with 32 and 64 scans for each experiment for the TOCSY and 
NOESY spectra, respectively, with a total of 4,882 real and imaginary points 
acquired in the directly detected dimension. A spin lock mix time of 250 ms was 
used for TOCSY spectra and a mix time of 150 ms was used for NOESY spectra. 
Water suppression was achieved by presaturation during the relaxation delay. 
For NOESY, saturation of the water peak was also applied during the mix time. 
NMRPipe and NMRView were used for data processing. Chemical shift 
assignments were performed manually. After complete spectral assignment of 
Oct-TriA1 and the Gram-negative lipid II analogue, the solutions were mixed and 
the TOCSY (70 ms mix time) and NOESY (125 ms mix time) data were acquired 
for the TriA1-Lipid II complex at 20 °C on a triple resonance HCN cryoprobe-
equipped Varian VNMRS 700 MHz spectrometer with z-axis pulsed-field 
gradients and VNMRJ 4.2A as host control. Spectral width for both experiments 
was 10,000 Hz in both the directly and indirectly detected dimensions. 256 
acquisitions were used to define the indirectly detected dimension, with 96 and 
128 scans for each experiment for the TOCSY and NOESY spectra, respectively, 
with a total of 8,192 real and imaginary points acquired in the directly detected 
dimension. 
Structure calculations: CYANA 2.1(33) was used to calculate the structure of 
Oct-TriA1 in DPC micelles with and without lipid II using automatically assigned 
NOE cross peaks. Custom library files for non-canonical amino acids were 
created based on energy minimized structures drawn with Avogadro. For Oct-
TriA1 in DPC micelles without lipid II, 211 crosspeak NOEs were selected and 
134 of these automatically assigned by CYANA (101 short-range, 13 medium-
range and 20 long-range) were used in the structure calculation. For Oct-TriA1 
with lipid II, 188 crosspeak NOEs (168 short-range, 14 medium-range and 6-
long-range) were used in the structure calculation. Seven cycles were done with 
10,000 steps per cycle giving 20 structures. Coordinates for the structure of Oct-
TriA1 in DPC micelles without lipid II have been deposited in the PDB (2n5w) and 
the chemical shifts deposited to BMRB (accession number 25737). Coordinates 
for the structure of Oct-TriA1 in DPC micelles with lipid II have been deposited in 
the PDB (2n5y) and the chemical shifts deposited to BMRB (accession number 
25741). Structures were generated from the CYANA output .pdb files using 
MacPyMOL. The structure with the lowest target function was used in 
subsequent docking studies. 
Docking studies with lipid II: CYANA was used to calculate the structure of 
lipid II in the presence of Oct-TriA1 using 67 NOEs restraints (64 short-range and 
3 medium-range). Out of the 20 calculated structures, the first structure had the 
lowest target function value and was used as the input ligand structure for 
docking studies. AutoDockTools (v. 1.5.6) was used to convert the lipid II and 
Oct-TriA1 .pdb files to .pdbqt files. The exhaustiveness was set to 8. Z,Z-Farnesyl 
Gram-negative lipid II was then docked into Oct-TriA1 using AutoDock Vina.(34) 
Lipid II analogue synthesis: See supplementary information. 
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Figure legends 
Figure 1. Structures of the tridecaptin analogues TriA1 and Oct-TriA1 
Figure 2. (A) Bacterial growth kinetics. Optical densities of E. coli cells exposed 
to 2x minimum inhibitory concentration (MIC) of ampicillin (8 μg/mL), 
chloramphenicol (32 μg/mL), tridecaptin A1 (6.25 μg/mL) and polymyxin B (4 
μg/mL). Tridecaptin A1 reduces cell density after twenty minutes of exposure. (B) 
Time-kill assays. E. coli cells were treated with 10xMIC of each antibiotic (50 μM) 
and the number of viable cells determined at different time points. Tridecaptin A1 
kills cells more slowly than polymyxin B. 
Figure 3. Inner-membrane assays. (A) Membrane depolarization assay. Addition 
of TriA1 to DiBAC4 treated E. coli cells decreases fluorescence by dilution but no 
membrane depolarization is observed. Polymyxin B leads to expected 
fluorescence increase as inner-membrane is depolarized. (B) Membrane 
disruption assay. Addition of TriA1 to SYTOX Green treated E. coli cells does not 
cause immediate pore formation. Triton X-100 causes rapid inner-membrane 
lysis. (C) Disruption of proton motive force detected as fluorescence decrease 
from BCECF-AM treated E. coli cells. Glucose increases the proton motive force, 
increasing the cytoplasmic pH and increasing fluorescence. Valinomycin 
disperses the electrochemical gradient and addition of TriA1 rapidly decreases 
fluorescence. Subsequent addition of nigericin further decreases fluorescence at 
a faster rate than TriA1. 
Figure 4. (A) Structure of Gram-negative and Gram-positive lipid II. (B) ITC of 
TriA1 + Gram-negative lipid II. (C) Spot-on-lawn assay with E. coli cells. Left = 
TriA1 (50 μM), middle = 1:1 TriA1 (100 μM):G+LII (100 μM) and right = 1:1 TriA1 
(100 μM):G-LII (100 μM).  TriA1 is active and premixing with Gram-positive lipid II 
(G+LII) slightly reduces the zone of inhibition. Premixing with Gram-negative lipid 
II (G-LII) abolishes activity. 
Figure 5. (A) In vitro assay measures formation of small proton pores. BCECF is 
encapsulated in LUVs with an internal pH of 8, whilst the external buffer is pH 6. 
Pore formation results in a proton gradient and decrease in fluorescence. (B) 
BCECF LUVs with no lipid II, 1 mol% Gram-negative lipid II or 1 mol% Gram-
positive lipid II are treated with 1.8 μM Oct-TriA1. Gram-negative lipid II 
significantly accelerates pore formation. 
Figure 6. Total synthesis of (Z,Z)-farnesyl Gram-negative lipid II (1). (a) TMSOTf, 
4Å MS, CH2Cl2, rt, 18h, 61%; (b) (i) ZnCl2, AcOH/Ac2O, rt, 24h (i) Zn, 
THF/AcOH/Ac2O, rt, 24h, 63% (2 steps); (c) (i) H2, Pd/C, MeOH, rt, 3h, (ii)   
(iPr)2NP(OBn)2, tetrazole, CH2Cl2, rt, 2h, (iii) 30% H2O2/THF, -78 oC, 2h, 84% (3 
steps); (d) DBU, CH2Cl2, rt, 0.5h, quant.; (e) Tetrapeptide 5, TFA/CH2Cl2, 2h; 
HATU, DIPEA, DMF, rt, 24h, 78%; (f) (i) H2, Pd/C, MeOH, rt, 2.5h, (ii) CDI 
activated (Z,Z)-farnesyl phosphate, DMF, rt, 4d, (iii) NaOH, H2O/dioxane, 37 oC, 
2 h, 25 % (3 steps). 
Figure 7. (A) NMR solution structure of TriA1 in DPC micelles containing Gram-
negative lipid II. Orange = hydrophobic residues, purple = D-Dab8 and cyan = 
other residues. (B) Lipid II analogue 1 docked into TriA1. Hydrophobic residues 
interact with the lipid II terpene tail and the pentapeptide occupies the binding 
pocket. (C) Modeled interaction shows H-bonding between D-Dab8 and DAP3. 
Figure 8. Resistance study with E. coli cells. 
 
